港股異動丨申洲國際(02313.HK)反彈超10% 績後獲多家券商唱好
格隆匯3月25日丨申洲國際(02313.HK)今日高開反彈,盤初一度急升超12%。現漲10.48%,報81.2港元,暫成交3.22億港元,最新總市值1220億港元。申洲國際日前公佈,2019年度純利約50.95億元(人民幣。下同),按年升12.2%,每股派1港元。主要客户的訂單需求繼續保持理想增長;年內集團海外生產基地的產能規模和生產效率進一步提升。中信證券點評稱,未知從國內演變至全球,是挑戰也是機遇,維持“買入”評級,目標價125港元。東吳證券則稱,面臨疫情挑戰,國際化及垂直一體化優勢持續鞏固。中金表示,淨利潤同比增長14.1%,符合預測,艱難時刻行業有望進一步整合。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.